Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 14/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 13/20 | 1.00 |
| ▸ | PRKDC | P78527 | 4/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | ABCC1 | P33527 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | TACR2 | P21452 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alpha-Naphthoflavone SCHEMBL121594 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2PRKDCCYP19A1 | |
| Alpha-Naphthoflavone SCHEMBL17292887 | 0.92 | CYP1A1 (0.84) | CYP1A1CYP1B1CYP1A2PRKDCCYP19A1 | |
| Alpha-Naphthoflavone SCHEMBL3665037 | 0.90 | CYP1A1 (0.82) | CYP1A1CYP1B1CYP1A2PRKDCCYP19A1 | |
| Alpha-Naphthoflavone SCHEMBL1906540 | 0.89 | CYP1A1 (0.80) | CYP1A1CYP1B1CYP1A2PRKDCCYP19A1 | |
| SCHEMBL4069839 | 0.88 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2PRKDCCYP19A1 | |
| SCHEMBL20594586 | 0.88 | CYP1A1 (0.78) | CYP1A1CYP1B1CYP1A2PRKDCCYP19A1 | |
| SCHEMBL29407618 | 0.88 | CYP1A1 (0.78) | CYP1A1CYP1B1CYP1A2PRKDCCYP19A1 | |
| SCHEMBL30917246 | 0.88 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2PRKDCCYP19A1 | |
| SCHEMBL31061133 | 0.88 | PRKDC (1.00) | CYP1A1CYP1B1CYP1A2PRKDCCYP19A1 | |
| SCHEMBL31061033 | 0.86 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2PRKDCCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003016-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2022-06-01 | — | — | EP | claimed |
| CN-113963752-A | Method and system for estimating biomass concentration in antibiotic fermentation process | 江南大学 | 2022-01-21 | — | — | CN | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-3952901-B1 | INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AS A BIOMARKER AND USES THEREOF | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025099307-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025026955-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-4334435-A1 | METHODS OF GENERATING MATURE HEPATOCYTES | Astellas Institute for Regenerative Medicine (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3362075-B1 | NATURAL KILLER CELLS AND ILC3 CELLS AND USES THEREOF | CELULARITY INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230142803-A1 | NATURAL KILLER CELLS AND ILC3 CELLS AND USES THEREOF | CELULARITY INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4157274-A1 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND CYP2C9 SUBSTRATES | Corcept Therapeutics Incorporated (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220195533-A1 | ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATION SIGNATURE AND METHODS FOR DETERMINING AHR SIGNALING STATUS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2022-06-23 | — | — | US | disclosed |
| US-20220170096-A1 | INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AS A BIOMARKER AND USES THEREOF | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2022-06-02 | — | — | US | disclosed |
| EP-4003016-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2022-06-01 | — | — | EP | disclosed |
| US-20220073498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| CN-114126634-A | Interleukin-4 inducible gene 1(IL4I1) as biomarker and use thereof | 德国癌症研究公共权益基金会 | 2022-03-01 | — | — | CN | disclosed |
| EP-3952901-A1 | INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AS A BIOMARKER AND USES THEREOF | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2022-02-16 | — | — | EP | disclosed |
| EP-3947734-A2 | ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATION SIGNATURE AND METHODS FOR DETERMINING AHR SIGNALING STATUS | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts (DE) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022024056-A1 | AN IMPROVED SUBSTRATE COCKTAIL ASSAY FOR HIGH-THROUGHPUT SCREENING OF CYTOCHROME P450 INHIBITORS | PIRAMAL PHARMA LIMITED (IN) | 2022-02-03 | — | — | WO | disclosed |
| CN-113963752-A | Method and system for estimating biomass concentration in antibiotic fermentation process | 江南大学 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | SSB, HLA-DRB1, UACA | CYP1A1 4603/4885CYP1B1 4684/4885CYP1A2 4527/4885 |
| US-20230142803-A1 | NATURAL KILLER CELLS AND ILC3 CELLS AND USES THEREOF | PBK, ILF3, IL2 | CYP1A1 4723/4885CYP1B1 4712/4885CYP1A2 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.